Design, Development and Evaluation f Nanostructured Lipid Carries Containing Resveratrol

Aim: To develop and evaluate Resveratrol-loaded Nanostructured Lipid Carriers (NLCs) for improved delivery, sustained release, and enhanced therapeutic potential in the management of diabetes mellitus. Objective:The objective of this research is to overcome the limitations of conventional antidiabetic therapies by formulating optimized nanostructured lipid carriers (NLCs) and evaluating their physicochemical properties, drug loading, release profile, and particle morphology via TEM. Method:Resveratrol-loaded NLCs were prepared using the high-speed homogenization method. Different formulations were developed by varying the concentration of solid lipids, liquid lipids, and surfactants. The prepared NLCs were characterized for particle size, zeta potential, drug loading capacity, and entrapment efficiency. TEM was used for morphological examination, and in vitro drug release studies were performed to determine release kinetics. Result:FTIR analysis was performed to identify functional groups and assess drug–excipient compatibility, revealing no incompatibility between the components. DSC analysis was used to determine the melting point of the drug and evaluate the influence of excipients, confirming the absence of interactions. The in vitro drug release study demonstrated improved release characteristics. The optimized formulation (CF3) showed a particle size of 196.2 nm, high drug content (97.26%), and excellent entrapment efficiency (94.29%). TEM imaging revealed smooth, spherical particles, confirming successful NLC formation. Stability studies under accelerated conditions indicated good physical stability, with no significant changes in physicochemical properties. Overall, the results suggest that Resveratrol-loaded NLCs have strong potential as an effective drug delivery system.